A lot of antibodies and antibody drug conjugates and whatever they call those other things coming your way? Thinking about how best to analyze these frustratingly impure things? It is crazy how a fine tuned evolutionary mechanism optimized over billions of years to make variable proteins to combat a near infinite number of biological obstacles can end up making varied proteins despite our 40 years of effort to make them make one thing at a time.
However, utilizing these things for our own designs is awesome and if you start accepting antibody characterization projects it can open the flood gates to crazy proteins.
Where are we at on de novo analysis of endogenous antibodies? Here is a great perspective from a team that knows a thing or two about it!